Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | VP, Strategic Communications | May 08, 2006 | May 09, 2006 |
| YIELD10 BIOSCIENCE, INC.YTEN · Entity 88195 | VP Planning and Communications | August 15, 2024 | August 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date May 08, 2006 · Filed May 09, 2006
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,199 |
Ending reported balance
After 2006-05-08 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2006-05-08 · Exercise / conversion · Acquired 1,000 · Balance 47,199 Row 2 · 2006-05-08 · Sale · Disposed 1,000 · Balance 46,199 F1: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1. Row 3 · 2006-05-08 · Exercise / conversion · Acquired 1,250 · Balance 47,449 Row 4 · 2006-05-08 · Sale · Disposed 1,250 · Balance 46,199 F1: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $15.56 · Expires 2006-12-11 | Direct | 279,183 |
Reported balance
After 2006-05-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2006-05-08 · Grant · Disposed 1,000 · Balance 279,183 F2: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 12/12/96. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.67 · Expires 2007-12-11 | Direct | 277,933 |
Reported balance
After 2006-05-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2006-05-08 · Grant · Disposed 1,250 · Balance 277,933 F3: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 12/12/97. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 6,793 |
Reported balance
Holding disclosure · report date 2006-05-08 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 6,793 |
| Common StockSEC Table I · non-derivative | IndirectOwned by husband | 10 |
Reported balance
Holding disclosure · report date 2006-05-08 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 10 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1.
F2: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 12/12/96.
F3: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 12/12/97.
YIELD10 BIOSCIENCE, INC.
Report date August 15, 2024 · Filed August 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,867 |
Reported balance
After 2024-08-15 transaction · row 1
1 source rowRow 1 · 2024-08-15 · Tax withholding · Disposed 731 · Balance 5,867 F1: Represents shares withheld in payment of withholding taxes upon partial vesting of RSUs granted 2/15/2024. F2: Share numbers reflect the 1:24 reverse stock split effected on 5/2/2024. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 2,056 |
Reported balance
Holding disclosure · report date 2024-08-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,056 F3: Shares acquired as Issuer matching contribution under the Yield10 Bioscience, Inc. 401(k) Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld in payment of withholding taxes upon partial vesting of RSUs granted 2/15/2024.
F2: Share numbers reflect the 1:24 reverse stock split effected on 5/2/2024.
F3: Shares acquired as Issuer matching contribution under the Yield10 Bioscience, Inc. 401(k) Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2006 Filed Mar 21, 2006 17:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $40.12 | $16,048.00 |
DisclosureSEC source: 0000875320-06-000029 · edgar.xml · nonDerivative · entry 3 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,187 F1 · kind: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1. Read SEC document |
| March 20, 2006 Filed Mar 21, 2006 17:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $40.12 | $40,120.00 |
DisclosureSEC source: 0000875320-06-000029 · edgar.xml · nonDerivative · entry 2 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,587 F1 · kind: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1. Read SEC document |
| March 20, 2006 Filed Mar 21, 2006 17:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,000 | $15.56 | $15,560.00 |
DisclosureSEC source: 0000875320-06-000029 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2006 Filed Mar 28, 2006 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $35.87 | $35,870.00 |
DisclosureSEC source: 0000875320-06-000033 · edgar.xml · nonDerivative · entry 2 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,199 F1 · kind: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1. Read SEC document |
| March 13, 2006 Filed Mar 14, 2006 17:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 1,000 | $0.00 Strike: $15.56 | $0.00 |
DisclosureSEC source: 0000875320-06-000026 · edgar.xml · derivative · entry 5 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,433 Underlying: Common Stock · 1,000 shares Expires 2006-12-11 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 12/12/96. Read SEC document |
| March 13, 2006 Filed Mar 14, 2006 17:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $37.23 | $37,230.00 |
DisclosureSEC source: 0000875320-06-000026 · edgar.xml · nonDerivative · entry 2 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,587 F1 · kind: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1. Read SEC document |
| March 13, 2006 Filed Mar 14, 2006 17:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,000 | $15.56 | $15,560.00 |
DisclosureSEC source: 0000875320-06-000026 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2006 Filed Mar 7, 2006 18:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 1,000 | $0.00 Strike: $15.56 | $0.00 |
DisclosureSEC source: 0000875320-06-000025 · edgar.xml · derivative · entry 5 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,433 Underlying: Common Stock · 1,000 shares Expires 2006-12-11 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 12/12/96. Read SEC document |
| March 06, 2006 Filed Mar 7, 2006 18:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $43.94 | $43,940.00 |
DisclosureSEC source: 0000875320-06-000025 · edgar.xml · nonDerivative · entry 2 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,587 F1 · kind: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1. Read SEC document |
| March 06, 2006 Filed Mar 7, 2006 18:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,000 | $15.56 | $15,560.00 |
DisclosureSEC source: 0000875320-06-000025 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2006 Filed Feb 28, 2006 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 1,000 | $0.00 Strike: $15.56 | $0.00 |
DisclosureSEC source: 0000875320-06-000023 · edgar.xml · derivative · entry 5 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,433 Underlying: Common Stock · 1,000 shares Expires 2006-12-11 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 12/12/96. Read SEC document |
| February 27, 2006 Filed Feb 28, 2006 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $43.87 | $43,870.00 |
DisclosureSEC source: 0000875320-06-000023 · edgar.xml · nonDerivative · entry 2 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,587 F1 · kind: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1. Read SEC document |
| February 27, 2006 Filed Feb 28, 2006 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,000 | $15.56 | $15,560.00 |
DisclosureSEC source: 0000875320-06-000023 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2006 Filed Feb 22, 2006 18:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 1,000 | $0.00 Strike: $15.56 | $0.00 |
DisclosureSEC source: 0000875320-06-000021 · edgar.xml · derivative · entry 5 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,433 Underlying: Common Stock · 1,000 shares Expires 2006-12-11 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 12/12/96. Read SEC document |
| February 21, 2006 Filed Feb 22, 2006 18:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $37.13 | $37,130.00 |
DisclosureSEC source: 0000875320-06-000021 · edgar.xml · nonDerivative · entry 2 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,587 F1 · kind: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1. Read SEC document |
| February 21, 2006 Filed Feb 22, 2006 18:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,000 | $15.56 | $15,560.00 |
DisclosureSEC source: 0000875320-06-000021 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2006 Filed Feb 14, 2006 17:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 1,000 | $0.00 Strike: $15.56 | $0.00 |
DisclosureSEC source: 0000875320-06-000018 · edgar.xml · derivative · entry 5 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,433 Underlying: Common Stock · 1,000 shares Expires 2006-12-11 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 12/12/96. Read SEC document |
| February 13, 2006 Filed Feb 14, 2006 17:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $34.96 | $34,960.00 |
DisclosureSEC source: 0000875320-06-000018 · edgar.xml · nonDerivative · entry 2 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,587 F1 · kind: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1. Read SEC document |
| February 13, 2006 Filed Feb 14, 2006 17:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,000 | $15.56 | $15,560.00 |
DisclosureSEC source: 0000875320-06-000018 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2006 Filed Feb 7, 2006 20:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 1,000 | $0.00 Strike: $15.56 | $0.00 |
DisclosureSEC source: 0000875320-06-000017 · edgar.xml · derivative · entry 5 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,433 Underlying: Common Stock · 1,000 shares Expires 2006-12-11 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 12/12/96. Read SEC document |
| February 06, 2006 Filed Feb 7, 2006 20:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $34.33 | $34,330.00 |
DisclosureSEC source: 0000875320-06-000017 · edgar.xml · nonDerivative · entry 2 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,587 F1 · kind: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1. Read SEC document |
| February 06, 2006 Filed Feb 7, 2006 20:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,000 | $15.56 | $15,560.00 |
DisclosureSEC source: 0000875320-06-000017 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2006 Filed Feb 6, 2006 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 14,066 | $0.00 Strike: $35.64 | $0.00 |
DisclosureSEC source: 0000875320-06-000014 · edgar.xml · derivative · entry 4 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,433 Underlying: Common stock · 14,066 shares Expires 2016-02-01 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/02/2006. Read SEC document |
| February 02, 2006 Filed Feb 6, 2006 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 3,240 | $0.01 | $32.40 |
DisclosureSEC source: 0000875320-06-000014 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,587 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting on 2/2/2010, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| January 31, 2006 Filed Feb 1, 2006 17:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 1,000 | $0.00 Strike: $15.56 | $0.00 |
DisclosureSEC source: 0000875320-06-000006 · edgar.xml · derivative · entry 5 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,367 Underlying: Common Stock · 1,000 shares Expires 2006-12-11 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 12/12/96. Read SEC document |
| January 31, 2006 Filed Feb 1, 2006 17:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $35.29 | $35,290.00 |
DisclosureSEC source: 0000875320-06-000006 · edgar.xml · nonDerivative · entry 2 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,196 F1 · kind: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1. Read SEC document |
| January 31, 2006 Filed Feb 1, 2006 17:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,000 | $15.56 | $15,560.00 |
DisclosureSEC source: 0000875320-06-000006 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2006 Filed Jan 24, 2006 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 1,000 | $0.00 Strike: $15.56 | $0.00 |
DisclosureSEC source: 0000875320-06-000003 · edgar.xml · derivative · entry 5 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,367 Underlying: Common Stock · 1,000 shares Expires 2006-12-11 F2 · derivative.exercise_date: Right to buy under 1995 Stock and Option Plan, vesting quarterly over 5 years from 12/14/95. Read SEC document |
| January 23, 2006 Filed Jan 24, 2006 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $33.63 | $33,630.00 |
DisclosureSEC source: 0000875320-06-000003 · edgar.xml · nonDerivative · entry 2 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,196 F1 · kind: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1. Read SEC document |
| January 23, 2006 Filed Jan 24, 2006 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,000 | $15.56 | $15,560.00 |
DisclosureSEC source: 0000875320-06-000003 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Strategic Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2006 Filed Jan 18, 2006 17:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 1,000 | $0.00 Strike: $15.56 | $0.00 |
DisclosureSEC source: 0000875320-06-000002 · edgar.xml · derivative · entry 5 BRUM LYNNE H · CIK 0001197017 · VP, Corp. Comm.&Financial Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,367 Underlying: Common Stock · 1,000 shares Expires 2006-12-11 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 12/12/96. Read SEC document |
| January 17, 2006 Filed Jan 18, 2006 17:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $33.62 | $33,620.00 |
DisclosureSEC source: 0000875320-06-000002 · edgar.xml · nonDerivative · entry 2 BRUM LYNNE H · CIK 0001197017 · VP, Corp. Comm.&Financial Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,196 F1 · kind: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1. Read SEC document |
| January 17, 2006 Filed Jan 18, 2006 17:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,000 | $15.56 | $15,560.00 |
DisclosureSEC source: 0000875320-06-000002 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Corp. Comm.&Financial Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2005 Filed Dec 7, 2005 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 2,000 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0000875320-05-000071 · edgar.xml · derivative · entry 5 BRUM LYNNE H · CIK 0001197017 · VP, Corp. Comm.&Financial Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,367 Underlying: Common Stock · 2,000 shares Expires 2005-12-13 F2 · derivative.exercise_date: Right to buy under 1995 Stock and Option Plan, vesting quarterly over 5 years from 12/14/95. Read SEC document |
| December 06, 2005 Filed Dec 7, 2005 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,000 | $24.80 | $49,600.00 |
DisclosureSEC source: 0000875320-05-000071 · edgar.xml · nonDerivative · entry 2 BRUM LYNNE H · CIK 0001197017 · VP, Corp. Comm.&Financial Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,196 F1 · kind: Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1. Read SEC document |
| December 06, 2005 Filed Dec 7, 2005 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,000 | $9.50 | $19,000.00 |
DisclosureSEC source: 0000875320-05-000071 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Corp. Comm.&Financial Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2005 Filed Jul 22, 2005 19:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 10,230 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0000875320-05-000043 · edgar.xml · derivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Corp. Comm.&Financial Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,367 Underlying: Common stock · 10,230 shares Expires 2015-07-19 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/20/2005. Read SEC document |
| February 03, 2005 Filed Feb 7, 2005 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 10,313 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-05-000007 · edgar.xml · derivative · entry 4 BRUM LYNNE H · CIK 0001197017 · VP, Corp. Comm.&Financial Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,137 Underlying: Common stock · 10,313 shares Expires 2015-02-02 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/03/2005. Read SEC document |
| February 03, 2005 Filed Feb 7, 2005 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,375 | $0.01 | $23.75 |
DisclosureSEC source: 0000875320-05-000007 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Corp. Comm.&Financial Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,196 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting on 2/3/2009, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| October 07, 2004 Filed Oct 12, 2004 18:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 7,500 | $0.00 Strike: $11.27 | $0.00 |
DisclosureSEC source: 0000875320-04-000105 · edgar.xml · derivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Corp. Comm.&Financial Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,824 Underlying: Common Stock · 7,500 shares Expires 2014-10-06 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 4 years. Read SEC document |
| May 06, 2004 Filed May 10, 2004 19:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 35,000 | $0.01 | $350.00 |
DisclosureSEC source: 0000875320-04-000048 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Corp. Comm.&Financial Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,821 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting 50% on May 6, 2009, subject to acceleration upon achievement of a performance-based milestone based on Company profitability, and 50% on May 6, 2007. Read SEC document |
| March 17, 2004 Filed Mar 19, 2004 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 6,000 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0000875320-04-000018 · edgar.xml · derivative · entry 4 BRUM LYNNE H · CIK 0001197017 · VP, Corp. Comm.&Financial Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,324 Underlying: Common stock · 6,000 shares Expires 2014-03-16 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 03/17/2004. Read SEC document |
| March 17, 2004 Filed Mar 19, 2004 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 800 | $0.01 | $8.00 |
DisclosureSEC source: 0000875320-04-000018 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Corp. Comm.&Financial Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,821 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting on 3/17/2008, subject to acceleration upon achievement of certain peformance-based milestones. Read SEC document |
| December 11, 2003 Filed Dec 15, 2003 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 6,000 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0000875320-03-000056 · edgar.xml · derivative · entry 4 BRUM LYNNE H · CIK 0001197017 · VP, Corp. Comm.&Financial Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,324 Underlying: Common stock · 6,000 shares Expires 2013-12-10 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 12/11/2003. Read SEC document |
| December 11, 2003 Filed Dec 15, 2003 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-03-000056 · edgar.xml · nonDerivative · entry 1 BRUM LYNNE H · CIK 0001197017 · VP, Corp. Comm.&Financial Plan 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,021 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting in 4 equal annual installments from 12/11/2003. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.